Background: Rehmannia glutinosa, a traditional Chinese herb, is commonly used to treat vascular-related disorders. Sepsis-associated vascular endothelial dysfunction is closely associated with mitochondrial damage. This study investigated the protective effects of secondary metabolites from R. glutinosa against LPS-induced mitochondrial dysfunction in endothelial cells, providing potential therapeutic insights into sepsis-related vascular complications. Methods: Phytochemical profiling of fresh R. glutinosa roots was conducted, and the structures of new secondary metabolites (1 and 2) were elucidated through comprehensive spectroscopic analysis and ECD calculations. UPLC-Q-TOF-MS/MS characterized phenylethanoid glycosides. Mitochondrial function was assessed by measuring the membrane potential, ROS levels, and TOM20/DRP1 expression in LPS-injured HUVECs. Results: Two novel eremophilane-type sesquiterpenes, remophilanetriols J (1) and K (2), along with five known phenylethanoid glycosides (3–7), were isolated from the fresh roots of R. glutinosa. UPLC-Q-TOF-MS/MS analysis revealed unique fragmentation pathways for phenylethanoid glycosides (3–7). In LPS-injured HUVECs, all compounds collectively restored the mitochondrial membrane potential, attenuated ROS accumulation, and modulated TOM20/DRP1 expression. In particular, remophilanetriol K (2) exhibited potent protective effects at a low concentration (1.5625 μM). Conclusions: This study identifies R. glutinosa metabolites as potential therapeutics for sepsis-associated vascular dysfunction by preserving mitochondrial homeostasis. This study provides a mechanistic basis for the traditional use of R. glutinosa and offers valuable insights into the development of novel therapeutics targeting mitochondrial dysfunction in sepsis.
Atherosclerosis remains the leading cause of cardiovascular mortality worldwide. Vascular smooth muscle cells (VSMCs) were long regarded as passive structural elements of the arterial wall, but they are now recognized as highly plastic cells capable of transdifferentiating into macrophage-like cells (MLCs). This conversion promotes plaque inflammation, matrix degradation, and necrotic core expansion, yet the mechanisms that control it remain poorly defined. This review synthesizes current understanding of the multilayered regulatory networks that govern VSMC-to-MLC transdifferentiation. These networks couple upstream signaling through MAPK, Notch, TGF-β, and PI3K/AKT to master transcription factors such as KLF4, IRF7, and ZEB2. They further extend to epigenetic mechanisms encompassing DNA methylation, histone modifications, non-coding RNAs, and metabolic reprogramming involving cholesterol efflux and lipophagy. We then assess therapeutic strategies that prevent or reverse this conversion, including miRNA replacement, kinase inhibition, LXR activation and autophagy induction. We further highlight unresolved questions on MLC heterogeneity, reversibility, and targeted delivery, outlining priorities for translating these insights into clinical benefit.